In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
HOME > TOP STORIES
TOP STORIES
-
ORGANIZATION As Off-Year Re-Pricing Looms, JPMA Chief Prods Govt to Minimize Product Coverage
January 7, 2020
-
REGULATORY MHLW to Set Up New Study Group on Detailing Activities Report System for All Medical Institutions
January 6, 2020
-
REGULATORY JETRO’s New York Office Gets First Health and Welfare Head in 2 Years
January 1, 2020
-
TRENDS 51 Drugs Listed in 2019 with Total Peak Sales Forecast of 370 Billion Yen, Many for Orphan Diseases
December 27, 2019
-
REGULATORY Councilor Mori Urges Drug Maker Management to Straighten Up as He Bids Farewell to MHLW
December 27, 2019
-
TRENDS Top 10 PHARMA JAPAN Articles in 2019
December 26, 2019
-
REGULATORY Japan's Global Health Confab to Prepare New Grand Design for Regulatory Harmonization in Asia
December 26, 2019
-
BUSINESS Opdivo/Yervoy Combo Filed for Frontline NSCLC in Japan
December 26, 2019
-
BUSINESS Kyowa Hakko Bio Hit with 18-Day Biz Suspension over GMP Failings
December 25, 2019
-
BUSINESS 15% Share Eyed for Jointly Developed Symbicort Generics, Toa Set to Push Uptake with Support App
December 25, 2019
-
BUSINESS Towa to Acquire Spanish Generic Player, Set to Venture into US/European Markets
December 24, 2019
-
BUSINESS Daiichi Sankyo, AZ Nab US Nod for ADC Enhertu in Breast Cancer
December 24, 2019
-
REGULATORY Fumi Yamamoto 1st Woman to Become MHLW’s Top Pharmacy Officer
December 23, 2019
-
REGULATORY Japan Approves Keytruda’s 1st Line RCC, Head and Neck Cancer Use, Bavencio’s Label Expansion and More
December 23, 2019
-
REGULATORY Japan Panel Hammers Out FY2020 Drug Pricing Reform
December 20, 2019
-
BUSINESS Biogen Eyes 2020 Aducanumab Filing in Japan Too, Nailing Down Re-Dosing Study Details
December 19, 2019
-
REGULATORY FY2020 Drug Price Revision to Shed 110 Billion Yen in Central Govt Spending
December 18, 2019
-
REGULATORY Promotion Guidelines Now in Full Effect, MHLW Starts Survey to Capture Leading Examples of Company Set-Ups
December 17, 2019
-
REGULATORY Chuikyo Settles on “Third Price Revision” for Expansion of Comparator PMP Deduction Rule
December 16, 2019
-
BUSINESS Keytruda on Track to Become a US$10 Billion Drug in 2019
December 13, 2019
ページ
The Ministry of Health, Labor and Welfare (MHLW) on December 18 presented a proposal to define the scope of products…
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
Will an “off-year” drug price revision happen in April 2025 or not? Over the last week, expectations have been up…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…